Tirzepatide vs Semaglutide: Zepbound vs Wegovy for Weight Loss, Diabetes & Heart Health in 2026

2026 Evidence-Based Guide

Last updated: October 6, 2026.

Tirzepatide and semaglutide are two of the most important incretin-based medicines used for obesity and metabolic disease. The key question is no longer simply whether they work. It is which drug has the better evidence for a particular goal, patient and indication.

Bottom line: In the strongest direct head-to-head obesity trial, tirzepatide produced greater average weight loss than semaglutide: 20.2% versus 13.7% at 72 weeks in SURMOUNT-5. However, semaglutide has important advantages, including a mature cardiovascular-outcomes evidence base, an oral Wegovy formulation, an FDA-approved 7.2-mg injectable dose for selected adults, pediatric obesity approval for Wegovy injection, and an FDA-approved MASH indication for Wegovy injection.

This guide focuses on U.S. regulatory labeling and major published evidence. Drug approvals, formulations, availability and prescribing rules differ by country.

In this guide

1. What is the difference between tirzepatide and semaglutide?
2. Which causes more weight loss?
3. What changed in 2026?
4. Which is better for type 2 diabetes?
5. Which is better for heart health?
6. Which drug fits which condition?
7. 2026 dose comparison
8. Side effects and safety
9. What about muscle loss?
10. What happens when you stop?
11. Can you switch between them?
12. Which one is better for you?
13. Frequently asked questions
14. Key sources

What is the difference between tirzepatide and semaglutide?

Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both the GIP receptor and the GLP-1 receptor, making it a dual incretin agonist. Both medicines can reduce appetite, slow gastric emptying and improve glucose regulation, but they act through different receptor profiles.

Semaglutide

• GLP-1 receptor agonist
• Brand names include Wegovy, Ozempic and Rybelsus in the U.S. for different indications
• Wegovy is available as a weekly injection and, in the U.S., a daily tablet
• Wegovy injection now has a 7.2-mg option for selected adults

Tirzepatide

• GIP + GLP-1 receptor agonist
• Brand names include Zepbound for obesity/OSA and Mounjaro for type 2 diabetes in the U.S.
• Administered by subcutaneous injection
• Maximum Zepbound dose: 15 mg once weekly

Tirzepatide vs semaglutide: which causes more weight loss?

For this question, the most important study is SURMOUNT-5, a phase 3b randomized trial published in the New England Journal of Medicine. It enrolled 751 adults with obesity, or overweight with an obesity-related complication, without type 2 diabetes. Participants received maximum tolerated doses of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks.

Tirzepatide

−20.2%

Least-squares mean change in body weight at week 72.

Semaglutide

−13.7%

Least-squares mean change in body weight at week 72.

The treatment difference was 6.5 percentage points in favor of tirzepatide. Waist circumference also fell more with tirzepatide: 18.4 cm versus 13.0 cm. The trial also found higher rates of achieving at least 10%, 15%, 20% and 25% weight loss with tirzepatide. E5 — direct randomized head-to-head evidence

Outcome at 72 weeks	Tirzepatide	Semaglutide	Interpretation
Mean body-weight change	−20.2%	−13.7%	Tirzepatide favored
Waist circumference	−18.4 cm	−13.0 cm	Tirzepatide favored
At least 10% weight loss	81.6%	60.5%	Tirzepatide favored
At least 15% weight loss	64.6%	40.1%	Tirzepatide favored
At least 20% weight loss	48.4%	27.3%	Tirzepatide favored
At least 25% weight loss	31.6%	16.1%	Tirzepatide favored

Read the SURMOUNT-5 PubMed record or the NEJM report.

Important: the SURMOUNT-5 comparison does not prove that tirzepatide is “better for everyone.” It answers a narrower question: in this population, at these maximum tolerated injectable doses, over 72 weeks, tirzepatide produced greater average weight loss than semaglutide.

Semaglutide vs Tirzepatide Comparison Chart (mobile responsive)

Both are once-weekly incretin-based medicines used for weight management and metabolic disease. Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide activates the GLP-1 receptor.

Feature

Semaglutide

Tirzepatide

Drug class

GLP-1 receptor agonist

Dual GIP + GLP-1 receptor agonist

Common obesity brand

Wegovy

Zepbound

Common diabetes brand

Ozempic

Mounjaro

How it works

Activates GLP-1 receptors, reducing appetite and food intake and improving glucose regulation.

Activates both GIP and GLP-1 receptors, affecting appetite, food intake and glucose metabolism.

Administration

Once-weekly injection

Once-weekly injection

Typical starting dose

0.25 mg once weekly

2.5 mg once weekly

Typical maintenance dose for obesity

1.7 or 2.4 mg once weekly

5, 10 or 15 mg once weekly

Maximum dose

2.4 mg/week

15 mg/week

Average weight-loss evidence

14.9% mean weight loss at 68 weeks in STEP 1

15.0%–20.9% mean weight loss at 72 weeks in SURMOUNT-1, depending on dose

Head-to-head weight loss

Lower average weight loss than tirzepatide in SURMOUNT-5

Superior average weight loss versus semaglutide at 72 weeks in SURMOUNT-5

Blood-glucose lowering

Strong

Generally stronger

Common side effects

Nausea, diarrhea, vomiting, constipation, abdominal discomfort

Nausea, diarrhea, vomiting, constipation, abdominal discomfort

GI tolerability

Gastrointestinal effects are common, particularly during dose escalation

Gastrointestinal effects are also common; comparative trial data suggest fewer GI-related discontinuations than semaglutide

Cardiovascular evidence

Established cardiovascular-outcome evidence; Wegovy is approved by the FDA to reduce major cardiovascular events in certain adults with overweight/obesity and established cardiovascular disease

Cardiovascular-outcome evidence is developing; weight and cardiometabolic benefits are well established

Lean-mass consideration

Weight loss can include lean mass; adequate protein, resistance training and overall nutrition are important

Weight loss can include lean mass; adequate protein, resistance training and overall nutrition are important

Potential advantage

Strong cardiovascular evidence and established clinical experience

Greater average weight loss and strong glucose-lowering efficacy

Key contraindication

Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2; serious hypersensitivity

Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2; serious hypersensitivity

Evidence note: Direct comparisons are more informative than comparing separate clinical trials. In SURMOUNT-5, adults with obesity without type 2 diabetes received maximum tolerated doses of tirzepatide or semaglutide for 72 weeks, with tirzepatide producing greater average reductions in body weight and waist circumference.

What changed in 2026?

The weight-loss landscape changed materially in 2026. Semaglutide is no longer limited to the older 2.4-mg injectable formulation in the U.S.

Wegovy HD 7.2 mg

In March 2026, the U.S. FDA approved Wegovy 7.2 mg once weekly for selected adults who tolerate 2.4 mg and need additional weight reduction. In the 72-week Study 8 population of adults with obesity and without type 2 diabetes, mean modeled weight change was −18.8% with 7.2 mg versus −15.5% with 2.4 mg and −3.9% with placebo.

But this is not a head-to-head result against tirzepatide. The 18.8% semaglutide result should not be directly compared with the 20.2% tirzepatide result as though the trials were identical. Differences in study design, populations, adherence, estimands and treatment exposure can affect cross-trial comparisons.

FDA: approval of higher-dose semaglutide · Current Wegovy labeling

Oral Wegovy

Wegovy tablets containing semaglutide 25 mg are also available in the U.S. The current label specifies once-daily administration on an empty stomach in the morning with up to 4 ounces of water, followed by at least 30 minutes before food, beverages or other oral medicines.

In the OASIS 4 trial, 25-mg oral semaglutide produced a modeled mean weight change of about −13.6% at week 64 in adults with obesity or overweight and a weight-related complication, without type 2 diabetes.

This gives semaglutide a route-of-administration advantage for people who strongly prefer a pill. However, oral semaglutide has not been directly compared with tirzepatide 15 mg in an equivalent randomized obesity trial.

OASIS 4 in NEJM · Wegovy prescribing information

Tirzepatide vs semaglutide for type 2 diabetes

For glucose lowering, tirzepatide also has strong direct evidence. In the 40-week SURPASS-2 trial, adults with type 2 diabetes taking metformin were randomized to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg weekly. All three tirzepatide doses produced greater HbA1c reduction than semaglutide 1 mg, and body-weight reductions were also greater with tirzepatide.

SURPASS-2 at 40 weeks	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg	Semaglutide 1 mg
HbA1c change	−2.01%	−2.24%	−2.30%	−1.86%
Body-weight change	−7.6 kg	−9.3 kg	−11.2 kg	−5.7 kg

The limitation matters: SURPASS-2 compared tirzepatide with semaglutide 1 mg, not the higher semaglutide doses used for obesity. It is therefore useful for type 2 diabetes, but it should not be treated as a definitive 2026 Zepbound-versus-Wegovy obesity trial.

SURPASS-2 PubMed record · NEJM

Which is better for heart health?

This is where a simple “tirzepatide wins” conclusion becomes misleading.

Semaglutide has mature randomized cardiovascular-outcome evidence in adults with established cardiovascular disease and overweight or obesity without diabetes. In the SELECT trial, the primary cardiovascular endpoint occurred in 6.5% with semaglutide versus 8.0% with placebo, corresponding to a hazard ratio of 0.80.

Tirzepatide also has growing cardiovascular and heart-failure evidence. In SURPASS-CVOT among people with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide for major cardiovascular events; the trial did not establish superiority over dulaglutide. Tirzepatide has additionally shown benefit on a composite of cardiovascular death or worsening heart failure in the SUMMIT trial among people with heart failure with preserved ejection fraction and obesity.

Semaglutide: stronger established CV evidence

SELECT directly demonstrated a reduction in major cardiovascular events versus placebo in an obesity population without diabetes.

E5 — hard cardiovascular outcomes

Tirzepatide: expanding CV evidence

Evidence includes noninferiority versus dulaglutide in T2D with ASCVD and favorable outcomes in obesity-related HFpEF.

E5 — randomized outcome trials

SELECT cardiovascular-outcomes trial · SURPASS-CVOT · SUMMIT HFpEF trial

Which drug fits which condition?

Rather than asking “Which drug is best?”, a more clinically useful question is: “Which medicine has an indication and evidence base that matches my treatment goal?”

Maximum average weight loss in direct obesity evidence

Tirzepatide

SURMOUNT-5 favored tirzepatide over semaglutide 1.7/2.4 mg.

Established CV event reduction in obesity without diabetes

Semaglutide

SELECT provides direct placebo-controlled cardiovascular outcomes evidence.

Moderate-to-severe OSA with obesity

Tirzepatide

Zepbound is FDA-approved for this indication in adults with obesity.

Noncirrhotic MASH with F2–F3 fibrosis

Semaglutide

Wegovy injection is FDA-approved under accelerated approval for this indication.

Pediatric obesity, age 12+

Semaglutide

Wegovy injection is FDA-approved for obesity in adolescents age 12 years and older.

Avoiding injections

Semaglutide

Wegovy tablets provide a daily oral option in the U.S.

FDA: Zepbound and obstructive sleep apnea · FDA: Wegovy and MASH · Current Wegovy label · Current Zepbound label

Tirzepatide vs semaglutide: 2026 dose comparison

Do not compare the milligram numbers directly. A 2.4-mg semaglutide dose is not “weaker” than a 2.5-mg tirzepatide dose simply because the number is smaller. They are different molecules with different potency and pharmacology.

Zepbound (tirzepatide)

Start: 2.5 mg once weekly for 4 weeks.

Escalation: increase by 2.5 mg increments after at least 4 weeks as needed and tolerated.

Weight-management maintenance: 5, 10 or 15 mg once weekly.

Maximum: 15 mg once weekly.

Wegovy injection (semaglutide)

Start: 0.25 mg once weekly for 4 weeks.

Usual maintenance: 1.7 or 2.4 mg once weekly, with 2.4 mg the recommended dose in many adult weight-management patients.

Higher dose: selected adults who tolerate 2.4 mg for at least 4 weeks may increase to 7.2 mg once weekly when additional weight reduction is clinically indicated.

Wegovy 25-mg tablet

Start: 1.5 mg once daily for 30 days.

Escalation: titrate every 30 days according to the prescribing information.

Maintenance: 25 mg once daily for adult cardiovascular-risk reduction and weight reduction.

Administration: morning, empty stomach, water only, up to 4 ounces; then wait at least 30 minutes before food, beverages or other oral medications.

Side effects and safety

Both medicines commonly cause gastrointestinal adverse effects, particularly during dose escalation. The most commonly reported reactions include nausea, diarrhea, vomiting, constipation and abdominal symptoms.

Issue	What to know	Evidence / source
GI side effects	Nausea, diarrhea, vomiting and constipation are common; severe GI reactions can occur.	Current FDA labeling
Pancreatitis	Acute pancreatitis has been observed. Persistent or severe abdominal pain warrants urgent medical assessment.	Current FDA labeling
Gallbladder disease	Gallstones and cholecystitis can occur; events may be associated with weight loss.	Current FDA labeling
Dehydration / kidney injury	Vomiting or diarrhea can cause volume depletion and acute kidney injury in susceptible patients.	Current FDA labeling
Severe gastroparesis	Neither Zepbound nor Wegovy is recommended in patients with severe gastroparesis.	Current FDA labeling
Thyroid C-cell tumors	Both labels carry a boxed warning based on rodent findings. Human risk remains unknown. Both are contraindicated with personal/family history of MTC or MEN2.	Current FDA labeling
Pregnancy	Both medicines may cause fetal harm and are not weight-loss treatments during pregnancy.	Current FDA labeling
Delayed gastric emptying	Both can affect absorption of oral medications and are relevant to anesthesia/sedation planning.	Current FDA labeling

Special point for tirzepatide: oral contraceptives

The current Zepbound label advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose escalation. Non-oral hormonal contraceptives should not be affected in the same way.

See the current Zepbound label.

Special point for 7.2-mg semaglutide: dysesthesia

In the current Wegovy labeling for the 7.2-mg injection studies, dysesthesia-type symptoms were reported more frequently with 7.2 mg than with 2.4 mg. The label groups symptoms such as burning, skin sensitivity, paresthesia and related sensations under dysesthesia.

Seek urgent medical care for severe or persistent abdominal pain, repeated vomiting with inability to keep fluids down, signs of severe dehydration, trouble breathing or swelling suggesting a serious allergic reaction, or other severe symptoms. This article cannot determine whether a symptom is caused by either medicine.

What about muscle loss?

Large weight loss is not composed of fat alone. Some loss of lean mass can occur during calorie restriction and pharmacological weight reduction. A body-composition analysis from SURMOUNT-1 found that tirzepatide-related weight loss included a substantially greater reduction in fat mass than lean mass, with roughly three quarters of the weight reduction coming from fat mass and about one quarter from lean mass in that analysis.

A 2025 systematic review and network meta-analysis similarly found that GLP-1 receptor agonist therapies can reduce lean mass as part of overall weight loss. This does not mean these medicines inevitably cause clinically important sarcopenia, but it does strengthen the case for resistance training, adequate dietary protein and attention to nutritional status during substantial weight loss.

People at higher risk of functional decline—particularly older adults or those starting with low muscle mass—may need a more individualized plan and periodic assessment of strength and function.

What happens when you stop?

Obesity is a chronic disease, and the biological drivers of appetite and weight regulation do not necessarily disappear when a medication is stopped. Clinical trials of incretin-based medicines have shown that stopping treatment can lead to weight regain in many patients.

That is why a better question than “When can I stop?” is “What is the long-term maintenance strategy?” That strategy may include continued pharmacotherapy, nutrition, resistance exercise, sleep, behavior change and management of the medical conditions contributing to weight gain.

A decision to stop or taper should be individualized with the prescribing clinician rather than based on a generic internet schedule.

Can you switch from semaglutide to tirzepatide—or vice versa?

Yes, clinicians sometimes switch patients between incretin medicines, but there is no universal milligram-for-milligram conversion. The appropriate approach depends on the current medication, dose, response, side effects, comorbidities, treatment goal and the time since the last dose.

The current Wegovy label does contain specific instructions for switching between Wegovy injection and Wegovy tablets. Those label-based instructions should not be interpreted as a conversion formula for switching between semaglutide and tirzepatide.

Do not combine semaglutide with tirzepatide unless specifically directed by the treating clinician. Current product labels do not recommend concomitant use with another GLP-1 receptor agonist.

Which one is better for you?

There is no single universal winner. The evidence supports a goal-based decision.

Choose tirzepatide more often when...

• Maximum average weight loss is the dominant goal.
• You have obesity and moderate-to-severe OSA and an FDA-approved indication applies.
• You have type 2 diabetes and need strong glucose lowering plus weight reduction.

Choose semaglutide more often when...

• Established cardiovascular disease is a major part of the treatment decision.
• You want an oral Wegovy option in the U.S.
• You fit an indication such as adolescent obesity or FDA-approved MASH treatment.

The practical decision checklist

Discuss these factors with your clinician: primary indication, expected weight-loss target, cardiovascular history, diabetes control, OSA, gastrointestinal tolerance, gallbladder or pancreatic history, medications taken by mouth, reproductive plans, prior response to GLP-1 therapy, muscle/functional status, cost and local availability.

OneDayMD approach: treat the indication, not the hype.

A medication that produces more weight loss on average is not automatically the best medication for a particular patient. The strongest comparison is the one that matches the drug to the disease, the outcome that matters most, and the person's ability to tolerate and sustain treatment.

Evidence grading used on this page

Grade	Meaning used here
E5	Large randomized trial, direct head-to-head comparison or randomized hard clinical outcome evidence.
E4	Randomized clinical trial or high-quality regulatory clinical-study evidence that addresses an important clinical outcome but is not a direct head-to-head answer to the main comparison.
E3	Systematic review, meta-analysis or well-conducted observational synthesis; useful for context but more vulnerable to heterogeneity or confounding.
E2–E0	Lower-level evidence, expert opinion, mechanistic reasoning or anecdotal claims. These should not override randomized or regulatory evidence.

Frequently asked questions

Is tirzepatide stronger than semaglutide for weight loss?

For injectable therapy in adults with obesity without type 2 diabetes, yes on the strongest direct head-to-head evidence: SURMOUNT-5 found greater average weight loss with tirzepatide than with semaglutide 1.7/2.4 mg over 72 weeks.

Does Wegovy 7.2 mg beat Zepbound?

We do not have a definitive head-to-head randomized trial comparing Wegovy 7.2 mg with tirzepatide 15 mg. Wegovy 7.2 mg produced 18.8% modeled mean weight loss at 72 weeks in one obesity trial, while SURMOUNT-5 reported 20.2% with tirzepatide against semaglutide 1.7/2.4 mg. Because these are different trials, they should not be treated as a direct comparison.

Is semaglutide or tirzepatide better for type 2 diabetes?

Tirzepatide produced greater HbA1c and body-weight reductions than semaglutide 1 mg in SURPASS-2. However, individual treatment decisions depend on glucose targets, other medications, cardiovascular and kidney considerations, tolerability and approved indications.

Which has fewer side effects?

Both commonly cause gastrointestinal adverse effects. Cross-trial percentages should not be compared casually because trial designs differ. In the direct SURMOUNT-5 study, most adverse events were gastrointestinal and were mainly mild to moderate, especially during dose escalation.

Can I take Ozempic and Zepbound together?

Routine combination is not recommended. Ozempic contains semaglutide and Zepbound contains tirzepatide; current product labeling does not recommend coadministration with another GLP-1 receptor agonist. Do not combine these medicines without explicit medical supervision.

Can I switch from Wegovy to Zepbound?

A clinician may switch a patient from one medicine to another, but there is no universal dose-conversion schedule. The timing and starting dose should be individualized based on the previous medicine, dose, side effects and clinical goals.

Does semaglutide cause less muscle loss than tirzepatide?

Current evidence does not justify a simple “semaglutide preserves muscle better” conclusion. Both can cause some lean-mass loss as part of substantial weight loss, and body-composition results depend on the study and degree of weight reduction. Resistance training, adequate protein and clinical monitoring are more actionable than choosing a drug solely on that assumption.

Can I take Wegovy tablets and Wegovy injections together?

No. The current Wegovy label does not recommend concomitant use of Wegovy tablets with semaglutide-containing products or another GLP-1 receptor agonist.

Key sources

SURMOUNT-5: Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393:26–36. DOI · PubMed

SURPASS-2: Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503–515. DOI · PubMed

SELECT: Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221–2232. DOI

OASIS 4: Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025;393:1077–1087. DOI

Current U.S. Wegovy label: DailyMed/NLM, revised June 2026. Label

Current U.S. Zepbound label: DailyMed/NLM, revised 2026. Label

FDA: Higher-dose semaglutide (Wegovy HD) approval, March 19, 2026. FDA announcement

FDA: Zepbound for moderate-to-severe OSA in adults with obesity, December 20, 2024. FDA announcement

FDA: Wegovy for noncirrhotic MASH with moderate-to-advanced fibrosis, August 15, 2025. FDA announcement

Medical disclaimer: This article is for educational purposes and is not a substitute for individualized medical advice, diagnosis or treatment. Prescription medicines should be used under the supervision of an appropriately qualified clinician. Regulatory information is U.S.-focused and may differ in Malaysia, the U.K., Australia, the EU and other jurisdictions. Always check the current local prescribing information before treatment decisions.